about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Bio­haven scores CGRP OK for acute mi­graine — can the com­mer­cial team catch up with Al­ler­gan on its de­but?

6 years ago
Pharma

FDA taps chemora­dio-sen­si­tiz­ing head and neck can­cer drug as 'break­through'

6 years ago
FDA+

Spark los­es an­oth­er top ex­ec in the wake of $4.3B takeover by Roche — re­port

6 years ago
People
Cell/Gene Tx

'The head­lines are the head­lines, but': Bio­Marin talks up po­ten­tial sav­ings as he­mo­phil­ia gene ther­a­py launch looms

6 years ago
Cell/Gene Tx

Fol­low­ing US, Chi­na hos­pi­tal ef­forts, Gilead plots its own PhI­II tri­als for close­ly watched Covid-19 drug

6 years ago
R&D
Coronavirus

Will a 'risk-of­f' mind­set has­ten cell ther­a­py M&A? Io­vance surges on buy­out chat­ter

6 years ago
Deals
Cell/Gene Tx

Ty­ing ba­sic sci­ence to spin­outs, Dana-Far­ber de­buts sis­ter funds to­tal­ing $126M with MPM Cap­i­tal

6 years ago
Financing
Discovery

Take­da swoops in to buy lit­tle biotech part­ner and its celi­ac drug poised to 'change stan­dard of care'

6 years ago
Deals

Theft vic­tim or da­ta bul­ly? IQVIA ex­changes blows with small ri­val it says de­stroyed ev­i­dence in le­gal fight

6 years ago
Outsourcing

When drug val­ue as­sess­ment meets re­al-world ev­i­dence: ICER en­lists Ae­tion in pric­ing eval­u­a­tion

6 years ago
Deals

NIH-part­nered Mod­er­na ships off its PhI-ready coro­n­avirus vac­cine can­di­date to a sea of un­cer­tain­ty

6 years ago
R&D

Eli Lil­ly scores ex­pand­ed MACE la­bel for Trulic­i­ty; Gilead­'s CAR-T Yescar­ta gets in Chi­na re­view line

6 years ago
News Briefing

FDA grants ‘break­through’ sta­tus to an­tibi­ot­ic al­ter­na­tive as Con­tra­Fect rush­es to join fight against su­per­bug

6 years ago
FDA+

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

6 years ago
China
Pharma

As coro­n­avirus out­break reach­es 'tip­ping point,' GSK lends ad­ju­vant tech to Chi­nese part­ner armed with pre­clin­i­cal ...

6 years ago
Deals
China

The fourth CGRP mi­graine drug is here. Time for Lund­beck to prove it's worth $2B

6 years ago
Pharma
FDA+

Bank­rupt an­tibi­otics mak­er Ar­a­digm turns to old part­ner/in­vestor for fi­nal $3M fire sale

6 years ago
Deals

Gene ther­a­py pi­o­neer Kathy High has left Spark af­ter com­plet­ing $4.3B union with Roche

6 years ago
People
Cell/Gene Tx

Fresh off $100M round, GV-backed re­al-world da­ta start­up woos Duke re­searcher as CMO

6 years ago
People
Startups

Don't let Ab­b­Vie fool FTC with an easy di­vesti­ture, plead crit­ics in lat­est at­tack on $63B Al­ler­gan buy­out

6 years ago
Deals
Pharma

Eli Lil­ly vet Ker­ry Blan­chard takes the helm at one of Chi­na's top deal­mak­ers, steer­ing to­ward first ap­provals

6 years ago
People
China

DuPont makes an­oth­er for­ay in­to drug R&D, throw­ing its name in­to the mi­cro­bio­me hat

6 years ago
Deals

Biotech CEO who lied about cur­ing his own paral­y­sis sen­tenced to 7 years in jail

6 years ago
People

Af­ter dig­ging through dis­cards, biotech start­up is mak­ing a $45M bet it can fix a failed can­cer ther­a­py

6 years ago
Financing
First page Previous page 80818283848586 Next page Last page
A service from the Financial Times